One month weight loss predicts the efficacy of Liraglutide in obese patients: data from a single center
Abstract
Objective: Liraglutide is a glucagon-like peptide 1 receptor agonist which acts through peripheral and central receptor pathways affecting food intake. Preliminary identification of responder patients represents a crucial point to reduce an inappropriate exposure to the drug and the health expenditure. The primary endpoint of our study was to identify predictors of liraglutide efficacy in the short term follow-up. The secondary endpoint was to evaluate the treatment efficacy stratified by the underlying psychiatric disorder. Methods: We evaluated a cohort of 100 patients (77 females, 23 males, mean body mass index 38.6 ± 3.2 kg/m 2) who were evaluated at baseline, and after 1, 3, and 6 months of treatment. Liraglutide efficacy was defined by a weight loss ≥5% of initial weight. Sociodemographic/metabolic parameters, food intake, smoking habit, and physical activity were correlated with liraglutide efficacy. Results: There was a significant weight loss after 1 month of therapy, as well as after 3 and 6 months when compared to the baseline (P<.0001; 27%, 45%, and 57% of patients showed a weight loss ≥5%, respectively). No difference was found in weight loss between the 3 groups of patients (with binge eating, with/without psychiatric disorders). The weight loss at 1 month was the only predictor of a positive response to the treatment. Conclusion: Our results confirm the efficacy of liraglutide even at a lower dose than conventional. The early response to the drug seems to be a good predictor of long-term efficacy and it might be useful in clinical practice to identify patients in whom liraglutide may induce a significant weight loss. Abbreviations: BMI = body mass index; EMA = European Medicine Agency; FDA = Food and Drug Administration; GLP-1 RA = glucagon-like peptide 1 receptor agonist.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other observational studies all found liraglutide beneficial.
“These findings are supported by other observational studies [51,52,58,59]; all of which found liraglutide beneficial as previously summarised in Table 2.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [58]
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · see citing works
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · see citing works
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works
Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity · doi:10.1002/oby.21629 · Cited by 131 · see citing works
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130 · see citing works
Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66 · see citing works
Prediction of response to sibutramine therapy in obese non‐diabetic and diabetic patients
Finer, N., Ryan, D. H., Renz, C. L., & Hewkin, A. C. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00481.x · Cited by 62 · see citing works
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine
and STO Study Group, Hainer, V., Kunešová, M., Bellisle, F., Hill, M., Braunerová, R. T., & Wagenknecht, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802850 · Cited by 56 · see citing works
le Roux, C. W., Aroda, V. R., Uddén, J., Cancino, A., Christensen, R. H. B., & Pi-Sunyer, X. (2017) · Obesity Facts · doi:10.1159/000478099 · Cited by 41 · see citing works
Garcia-Lacarte, M., Martínez, J. A., Zulet, M. Á., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201217 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06211-9 · Cited by 92 · see citing works
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53 · see citing works
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
Ferrari, F., Fierabracci, P., Salvetti, G., Jaccheri, R., Vitti, J., Scartabelli, G., Meola, A., Magno, S., Ceccarini, G., & Santini, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01334-1 · Cited by 29 · see citing works
Potential contributors to variation in weight‐loss response to liraglutide
Webster, C. M., Mittal, N., Dhurandhar, E. J., & Dhurandhar, N. V. (2023) · Obesity Reviews · doi:10.1111/obr.13568 · Cited by 19 · see citing works
Rocha-González, H. I., De la Cruz-Álvarez, L. E., Kammar-García, A., Canizales-Quinteros, S., Huerta-Cruz, J. C., Barranco-Garduño, L. M., & Reyes-García, J. G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121354 · Cited by 10 · see citing works
- Authors
- Maccora, C., Ciuoli, C., Goracci, A., Benenati, N., Formichi, C., Pilli, T., Verdino, V., Mnutr, O. N., Bufano, A., Tirone, A., Voglino, C., Fagiolini, A., & Castagna, M. G.
- Affiliations
- University of Siena (IT)
- Corresponding author
- Ciuoli, Cristina
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 26
- Issue
- 2
- Pages
- 235-240
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2984454195
- Cited by
- 19
- References
- 13
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 2
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- liraglutide, obesity, weight loss, GLP-1 receptor agonists, predictors of treatment response, early response, binge eating, mental illness, dietary intake
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Body Weight, Female, Humans, Hypoglycemic Agents, Male, Obesity, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
